Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Anesthesiology. 2009 Nov;111(5):1111–1119. doi: 10.1097/ALN.0b013e3181bbcc26

Table 1.

Study Groups.

Group Name Drug Concentration
Group 1
(n = 10)		 Ropivacaine
Group 2
(n = 10)		 Ropivacaine +
2.7 ± 0.2 μM (0.5 μg/kg) DEX
Group 3
(n = 10)		 Ropivacaine +
11.7 ± 0.8 μM (2.0 μg/kg) DEX
Group 4
(n = 10)		 Ropivacaine +
34.1 ± 3.0 μM (6.0 μg/kg) DEX
Group 5
(n = 10)		 Ropivacaine +
120.6 ± 6.4 μM (20.0 μg/kg) DEX

The five different study groups are noted above. Groups 2-5 represent the experimental doses that evaluate the dose-dependent effects of dexmedetomidine, in combination with ropivacaine, on the duration of analgesia from a sciatic nerve block. Dexmedetomidine doses were calculated based on weight (μg/kg). The ropivacaine concentration (0.5%) and total volume injected (0.2 ml) were constant between all groups. Group 1 represents the control group. DEX = dexmedetomidine.